Skip to main content

Table 4 Association of TSR with other clinicopathological factors

From: The prognostic significance of tumour-stroma ratio in endometrial carcinoma

Factor N (%) TSR, median (IQR) P
All patients 400 (100) 3.3 (2.0–5.3)  
Age    
 <55 56 (14) 3.0 (1.8–4.0)a 0.019
 55–64 125 (31) 3.4 (2.0–5.3)a,b  
 65–74 134 (34) 3.0 (1.9–5.4)a,b  
 ≥75 85 (21) 4.7 (2.5–6.0)b  
Stage (FIGO 2009)    
 I 230 (58) 3.0 (1.8–4.9) 0.192
 II 71 (18) 4.0 (2.5–6.6)  
 III 75 (19) 3.6 (2.1–5.3)  
 IV 24 (6) 4.8 (2.6–6.2)  
Grade    
 1 149 (37) 2.8 (1.7–4.8)a <0.001
 2 106 (27) 3.2 (1.9–4.9)a,b  
 3 145 (36) 4.1 (2.3–6.0)b  
Histology    
 Endometrioid (EEC) 302 (75.5) 3.2 (2.0–5.1) 1.000
 Non–EEC 48 (12) 3.9 (2.2–6.6)  
 Mixed EEC/non-EEC 50 (12.5) 3.3 (1.9–5.4)  
Depth of myometrial invasion    
 Inner half 210 (52.5) 3.1 (1.7–5.6) 1.000
 Outer half 190 (47.5) 3.6 (2.2–5.0)  
Cervical involvement    
 No 261 (65) 3.0 (1.7–5.0) 0.108
 Yes 128 (32) 3.7 (2.3–5.4)  
 Missing data 11 (3) -  
Lymph nodes positive    
 No 274 (68.5) 3.3 (2.0–5.3) 1.000
 Yes 50 (12.5) 3.8 (2.2–5.8)  
 No lymphadenectomy 76 (19) -  
Lymphovascular invasion    
 No 203 (51) 2.9 (1.6–4.8) <0.001
 Yes 193 (48) 3.9 (2.2–5.8)  
 Missing data 4 (1) -  
Adjuvant treatment    
 No 240 (60) 3.2 (1.9–5.2) 1.000
 Yes 160 (40) 3.6 (2.1–5.4)  
  1. Data were analysed by Mann–Whitney U tests or Kruskal-Wallace tests, as appropriate. P-values following correction for multiple comparisons (Holm’s sequential Bonferroni method) are indicated. a,bDepict significant differences between categories following post-hoc Mann–Whitney U tests
  2. Abbreviations: EEC endometrioid endometrial carcinoma, FIGO international federation of gynaecology and obstetrics, IQR interquartile range